The National Cancer Institute gave Chrysalis BioTherapeutics $1.5 million for the continued development of Chrysalin, a regenerative peptide that could lessen radiotherapy-induced brain tissue damage. In clinical trials involving skin healing and bone repair, adverse events were not reported, said Darrell H. Carney, founder and CEO of Chrysalis.

Related Summaries